EV Suseong discusses supply of 'Kobixil' COVID-19 prevention spray with Chinese Daecheon Bio

[Asia Economy Reporter Jang Hyowon] EV Suseong announced on the 29th that it is discussing the supply of Kobixil with Anhui Dachuan Bioengineering Co., Ltd. (hereinafter Dachuan Bio) in China through its affiliate Salvacion.

Dachuan Bio belongs to the category of 'biochemical in vitro diagnostic reagent innovative enterprises' authorized to manufacture and produce 127 types of in vitro diagnostic reagents approved by the central government of China and the Anhui provincial authorities. The company explained that, including the current supply discussions with Dachuan Bio, various local companies are flooding with supply requests for Kobixil.

Earlier, Salvacion signed a supply contract for D35 and Kobixil in China on the 27th. D35 is a company that signed an exclusive supply contract for Korean pharmaceuticals in China with Shanghai Zhongzhi Economic and Technological Joint Venture Corporation (hereinafter Shanghai Zhongzhi), a subsidiary of China International Intellectual Property Cooperation Group Co., Ltd. (hereinafter Zhongzhi Group). Salvacion plans to supply up to 1 billion Kobixil units to Shanghai Zhongzhi.

An EV Suseong official said, "Recently, the number of confirmed COVID-19 cases in China has surged, and the emergence of variant viruses has worsened the severity," adding, "As the importance of preventive measures increases, orders and supply discussions for Kobixil are ongoing."

He continued, "We are making every effort to secure raw materials for smooth supply and are also considering additional production line expansions."

Kobixil is a 99.9% COVID-19 preventive nasal spray independently developed by Salvacion. By spraying 2 to 3 times a day, it forms a physical protective barrier inside the nasal cavity to block the virus from entering the human body. It has proven efficacy in preventing various respiratory viruses including COVID-19 and was the world's first spray approved to prevent COVID-19 virus and common colds.

Meanwhile, Salvacion Investment Association is the largest shareholder holding 11.39% of EV Suseong's shares. EV Suseong announced on the 27th that it plans to change its trade name to Suseong Salvacion.

This content was produced with the assistance of AI translation services.